Pliant Therapeutics: Strange Volatility #Pliant #Therapeutics #Strange #Volatility
Tag: Therapeutics
Travere therapeutics director Roy Baynes sells $220,000 in stock
Travere therapeutics director Roy Baynes sells $220,000 in stock#Travere #therapeutics #director #Roy #Baynes #sells #stock
Applied Therapeutics (APLT) Investors are Alerted of the Pending Class Action and are Urged to Contact BFA Law by February 18 Deadline
Applied Therapeutics (APLT) Investors are Alerted of the Pending Class Action and are Urged to Contact…
Apogee Therapeutics CEO Michael Henderson sells $608,700 in stock
Apogee Therapeutics CEO Michael Henderson sells $608,700 in stock#Apogee #Therapeutics #CEO #Michael #Henderson #sells #stock
Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD
Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD #Coya #Therapeutics #Pivots #Phase #ALS…
Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript
Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript #Iterum #Therapeutics #plc #ITRM #Earnings #Call #Transcript
Spero Therapeutics COO Timothy Keutzer sells shares for $44,097
Spero Therapeutics COO Timothy Keutzer sells shares for $44,097#Spero #Therapeutics #COO #Timothy #Keutzer #sells #shares
APLT DEADLINE: Applied Therapeutics Investors Urged to Contact BFA Law before February 18 Class Action Deadline
APLT DEADLINE: Applied Therapeutics Investors Urged to Contact BFA Law before February 18 Class Action Deadline#APLT…
Bicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable Data (BCYC)
This article was written by Follow Avisol Capital Partners is made up of a team of…
SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025
SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20,…
Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference
Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference#Beam #Therapeutics #Participate #Guggenheim #SMID #Cap #Biotech…
Enliven Therapeutics CFO sells $70,177 in stock
Enliven Therapeutics CFO sells $70,177 in stock#Enliven #Therapeutics #CFO #sells #stock
The Stock That’s Making Waves: Akero Therapeutics (AKRO)
Today was a day of surprises in the market, and one stock that caught my attention…
ROSEN, A TOP-RANKED LAW FIRM, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action
New York, New York–(Newsfile Corp. – January 26, 2025) – WHY: Rosen Law Firm, a global…
Investors of Applied Therapeutics are Encouraged to Contact Kaplan Fox Before the February 18, 2025 Lead Plaintiff Deadline By Investing.com
NEW YORK – January 25, 2025 (NEWMEDIAWIRE) – Kaplan Fox & Kilsheimer LLP announces that a…
A Securities Fraud Class Action Lawsuit Has Been Filed Against Applied Therapeutics, Inc. (APLT) By Investing.com
Radnor, Pennsylvania–(Newsfile Corp. – January 25, 2025) – The law firm of Kessler Topaz Meltzer &…
Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials
Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials #YmAbs #Therapeutics #Finding #Direction #Murk #Clinical…
Dyne Therapeutics: Moving Forward On 2 Key Fronts
Dyne Therapeutics: Moving Forward On 2 Key Fronts #Dyne #Therapeutics #Moving #Key #Fronts
Beam Therapeutics: Too Expensive For Me, But Watch For Important Catalysts
Beam Therapeutics: Too Expensive For Me, But Watch For Important Catalysts #Beam #Therapeutics #Expensive #Watch #Important…
Odyssey Therapeutics Begins IPO Rollout
Odyssey Therapeutics Begins IPO Rollout #Odyssey #Therapeutics #Begins #IPO #Rollout
Viking Therapeutics: The Turning Point Is Not Here Yet
Viking Therapeutics: The Turning Point Is Not Here Yet #Viking #Therapeutics #Turning #Point
Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension
Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension #Mineralys #Therapeutics #Lorundrostat #Worth #Shot…